-
Je něco špatně v tomto záznamu ?
Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study
Z. Megyesfalvi, N. Barany, A. Lantos, Z. Valko, O. Pipek, C. Lang, A. Schwendenwein, F. Oberndorfer, S. Paku, B. Ferencz, K. Dezso, J. Fillinger, Z. Lohinai, J. Moldvay, G. Galffy, B. Szeitz, M. Rezeli, C. Rivard, FR. Hirsch, L. Brcic, H. Popper,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
35489038
DOI
10.1002/path.5922
Knihovny.cz E-zdroje
- MeSH
- lidé MeSH
- malobuněčný karcinom plic * genetika metabolismus chirurgie MeSH
- nádorové buněčné linie MeSH
- nádory plic * genetika metabolismus chirurgie MeSH
- prognóza MeSH
- proteomika MeSH
- regulace genové exprese u nádorů MeSH
- transkripční faktory bHLH genetika metabolismus MeSH
- transkripční faktory genetika metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
The tissue distribution and prognostic relevance of subtype-specific proteins (ASCL1, NEUROD1, POU2F3, YAP1) present an evolving area of research in small-cell lung cancer (SCLC). The expression of subtype-specific transcription factors and P53 and RB1 proteins were measured by immunohistochemistry (IHC) in 386 surgically resected SCLC samples. Correlations between subtype-specific proteins and in vitro efficacy of various therapeutic agents were investigated by proteomics and cell viability assays in 26 human SCLC cell lines. Besides SCLC-A (ASCL1-dominant), SCLC-AN (combined ASCL1/NEUROD1), SCLC-N (NEUROD1-dominant), and SCLC-P (POU2F3-dominant), IHC and cluster analyses identified a quadruple-negative SCLC subtype (SCLC-QN). No unique YAP1-subtype was found. The highest overall survival rates were associated with non-neuroendocrine subtypes (SCLC-P and SCLC-QN) and the lowest with neuroendocrine subtypes (SCLC-A, SCLC-N, SCLC-AN). In univariate analyses, high ASCL1 expression was associated with poor prognosis and high POU2F3 expression with good prognosis. Notably, high ASCL1 expression influenced survival outcomes independently of other variables in a multivariate model. High POU2F3 and YAP1 protein abundances correlated with sensitivity and resistance to standard-of-care chemotherapeutics, respectively. Specific correlation patterns were also found between the efficacy of targeted agents and subtype-specific protein abundances. In conclusion, we investigated the clinicopathological relevance of SCLC molecular subtypes in a large cohort of surgically resected specimens. Differential IHC expression of ASCL1, NEUROD1, and POU2F3 defines SCLC subtypes. No YAP1-subtype can be distinguished by IHC. High POU2F3 expression is associated with improved survival in a univariate analysis, whereas elevated ASCL1 expression is an independent negative prognosticator. Proteomic and cell viability assays of human SCLC cell lines revealed distinct vulnerability profiles defined by transcription regulators. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
1st Department of Pathology and Experimental Cancer Research Semmelweis University Budapest Hungary
Department of Biomedical Engineering Lund University Lund Sweden
Department of Pathology Medical University of Vienna Vienna Austria
Department of Physics of Complex Systems Eotvos Lorand University Budapest Hungary
Department of Thoracic Surgery Klinik Floridsdorf Vienna Austria
Diagnostic and Research Institute of Pathology Medical University of Graz Graz Austria
Division of Medical Oncology University of Colorado Anschutz Medical Campus Aurora CO USA
MTA SE NAP Brain Metastasis Research Group Hungarian Academy of Sciences Budapest Hungary
National Koranyi Institute of Pulmonology Budapest Hungary
Tisch Cancer Institute Center for Thoracic Oncology Mount Sinai Health System New York NY USA
Torokbalint County Institute of Pulmonology Torokbalint Hungary
University Clinic for Respiratory and Allergic Diseases Golnik Golnik Slovenia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025064
- 003
- CZ-PrNML
- 005
- 20221031100209.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/path.5922 $2 doi
- 035 __
- $a (PubMed)35489038
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Megyesfalvi, Zsolt $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 245 10
- $a Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study / $c Z. Megyesfalvi, N. Barany, A. Lantos, Z. Valko, O. Pipek, C. Lang, A. Schwendenwein, F. Oberndorfer, S. Paku, B. Ferencz, K. Dezso, J. Fillinger, Z. Lohinai, J. Moldvay, G. Galffy, B. Szeitz, M. Rezeli, C. Rivard, FR. Hirsch, L. Brcic, H. Popper, I. Kern, M. Kovacevic, J. Skarda, M. Mittak, G. Marko-Varga, K. Bogos, F. Renyi-Vamos, MA. Hoda, T. Klikovits, K. Hoetzenecker, K. Schelch, V. Laszlo, B. Dome
- 520 9_
- $a The tissue distribution and prognostic relevance of subtype-specific proteins (ASCL1, NEUROD1, POU2F3, YAP1) present an evolving area of research in small-cell lung cancer (SCLC). The expression of subtype-specific transcription factors and P53 and RB1 proteins were measured by immunohistochemistry (IHC) in 386 surgically resected SCLC samples. Correlations between subtype-specific proteins and in vitro efficacy of various therapeutic agents were investigated by proteomics and cell viability assays in 26 human SCLC cell lines. Besides SCLC-A (ASCL1-dominant), SCLC-AN (combined ASCL1/NEUROD1), SCLC-N (NEUROD1-dominant), and SCLC-P (POU2F3-dominant), IHC and cluster analyses identified a quadruple-negative SCLC subtype (SCLC-QN). No unique YAP1-subtype was found. The highest overall survival rates were associated with non-neuroendocrine subtypes (SCLC-P and SCLC-QN) and the lowest with neuroendocrine subtypes (SCLC-A, SCLC-N, SCLC-AN). In univariate analyses, high ASCL1 expression was associated with poor prognosis and high POU2F3 expression with good prognosis. Notably, high ASCL1 expression influenced survival outcomes independently of other variables in a multivariate model. High POU2F3 and YAP1 protein abundances correlated with sensitivity and resistance to standard-of-care chemotherapeutics, respectively. Specific correlation patterns were also found between the efficacy of targeted agents and subtype-specific protein abundances. In conclusion, we investigated the clinicopathological relevance of SCLC molecular subtypes in a large cohort of surgically resected specimens. Differential IHC expression of ASCL1, NEUROD1, and POU2F3 defines SCLC subtypes. No YAP1-subtype can be distinguished by IHC. High POU2F3 expression is associated with improved survival in a univariate analysis, whereas elevated ASCL1 expression is an independent negative prognosticator. Proteomic and cell viability assays of human SCLC cell lines revealed distinct vulnerability profiles defined by transcription regulators. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 650 _2
- $a transkripční faktory bHLH $x genetika $x metabolismus $7 D051792
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory plic $x genetika $x metabolismus $x chirurgie $7 D008175
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proteomika $7 D040901
- 650 12
- $a malobuněčný karcinom plic $x genetika $x metabolismus $x chirurgie $7 D055752
- 650 _2
- $a transkripční faktory $x genetika $x metabolismus $7 D014157
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Barany, Nandor $u National Koranyi Institute of Pulmonology, Budapest, Hungary $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Lantos, Andras $u National Koranyi Institute of Pulmonology, Budapest, Hungary
- 700 1_
- $a Valko, Zsuzsanna $u National Koranyi Institute of Pulmonology, Budapest, Hungary $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Pipek, Orsolya $u Department of Physics of Complex Systems, Eotvos Lorand University, Budapest, Hungary
- 700 1_
- $a Lang, Christian $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Schwendenwein, Anna $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Oberndorfer, Felicitas $u Department of Pathology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Paku, Sandor $u 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000326647729
- 700 1_
- $a Ferencz, Bence $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary
- 700 1_
- $a Dezso, Katalin $u 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Fillinger, Janos $u National Koranyi Institute of Pulmonology, Budapest, Hungary
- 700 1_
- $a Lohinai, Zoltan $u National Koranyi Institute of Pulmonology, Budapest, Hungary
- 700 1_
- $a Moldvay, Judit $u National Koranyi Institute of Pulmonology, Budapest, Hungary $u MTA-SE NAP, Brain Metastasis Research Group, Hungarian Academy of Sciences, Budapest, Hungary
- 700 1_
- $a Galffy, Gabriella $u Torokbalint County Institute of Pulmonology, Torokbalint, Hungary
- 700 1_
- $a Szeitz, Beata $u Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Rezeli, Melinda $u Department of Biomedical Engineering, Lund University, Lund, Sweden
- 700 1_
- $a Rivard, Christopher $u Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
- 700 1_
- $a Hirsch, Fred R $u Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA $u Tisch Cancer Institute, Center for Thoracic Oncology, Mount Sinai Health System, New York, NY, USA
- 700 1_
- $a Brcic, Luka $u Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Popper, Helmut $u Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria $1 https://orcid.org/0000000349701265
- 700 1_
- $a Kern, Izidor $u University Clinic for Respiratory and Allergic Diseases Golnik, Golnik, Slovenia
- 700 1_
- $a Kovacevic, Mile $u University Clinic for Respiratory and Allergic Diseases Golnik, Golnik, Slovenia
- 700 1_
- $a Skarda, Jozef $u Institute of Clinical and Molecular Pathology, Medical Faculty, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Pathology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Mittak, Marcel $u Department of Surgery, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Marko-Varga, Gyorgy $u Department of Biomedical Engineering, Lund University, Lund, Sweden
- 700 1_
- $a Bogos, Krisztina $u National Koranyi Institute of Pulmonology, Budapest, Hungary
- 700 1_
- $a Renyi-Vamos, Ferenc $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary
- 700 1_
- $a Hoda, Mir Alireza $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Klikovits, Thomas $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Thoracic Surgery, Klinik Floridsdorf, Vienna, Austria
- 700 1_
- $a Hoetzenecker, Konrad $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Schelch, Karin $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Laszlo, Viktoria $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Dome, Balazs $u Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary $u National Koranyi Institute of Pulmonology, Budapest, Hungary $u Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000187998624
- 773 0_
- $w MED00002878 $t Journal of pathology $x 1096-9896 $g Roč. 257, č. 5 (2022), s. 674-686
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35489038 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100207 $b ABA008
- 999 __
- $a ok $b bmc $g 1854662 $s 1176354
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 257 $c 5 $d 674-686 $e 20220525 $i 1096-9896 $m Journal of pathology $n J Pathol $x MED00002878
- LZP __
- $a Pubmed-20221017
